In response to the urgent need for timely, evidence-informed decisions during the peak of the COVID-19 pandemic, the MSSU began producing rapid evidence summaries on drug treatments and preventatives. These summaries were updated on a fixed schedule and addressed the ongoing need to evaluate constantly evolving evidence, including data from traditional academic sources and grey literature such as news releases and regulatory updates. This work supported the Nova Scotia Emerging and Re-Emerging Infectious Diseases Therapeutics and Prophylactics Review Group to guide decision-making. This also informed protocol updates to the CO-VIC Study for treatment of hospitalized patients with COVID-19. By keeping key decision-makers informed, this work contributed to the rapid and responsible use of therapeutic options during the ongoing management of COVID-19.
What we learned
Summary: Background Summary Tocilizumab for COVID-19 (This is an example only and may not accurately reflect the information as of today).